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PREGNANCY AFTER LIVER TRANSPLANTATION WITH 
TACROLIMUS IMMUNOSUPPRESSION: A SINGLE CENTER'S 
EXPERIENCE UPDATE AT 13 YEARS1 
AsHOKKUl.VIAR B. JAIN,2,3 J, REYES,2 AMADEO MARCOS,2 G. MAzARIEGOS,2 BIJAN EGHTESAD,2 
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ANN RAFAIL,2 THOMAS E. STARZL,2 AND JOHN J. FUNG2 
Background. Chronic liver disease often leads to am-
enorrhea in women of childbearing age. There are 
several reports of successful pregnancy after liver 
transplantation (LTx) with cyclosporine A immuno-
suppression. Tacrolimus has been increasingly used in 
solid-organ transplantation, and the effect of the drug 
on pregnancy is still of interest to clinicians. This 
study updates our single-center experience. 
Methods. All pregnancies after LTx with tacrolimus 
immunosuppression were followed prospectively. Pa-
tients' clinical courses during pregnancy and labor 
along with gestational period and birth weight were 
catalogued. Changes in liver function, renal function, 
and immunosuppression also were recorded. The 
birth weight percentile was calculated on the basis of 
the gestational period using a standard chart. 
Results. Thirty-seven mothers delivered 49 babies. 
Three mothers delivered three times, and six mothers 
delivered two times. Thirty-six mothers (97%) survived 
the pregnancy, and 36 allografts (97%) survived. The 
one death and graft loss was in a patient who demon-
strated infra-aortic arterial graft, which clotted by the 
gravid uterus during labor. The patient developed a 
gangrenous liver and died before she could undergo 
retransplantation. The mean gestational period was 
36.4±3.2 weeks, excluding two premature deliveries at 
23 and 24 weeks gestation. Twenty-two babies (46.9%) 
were delivered by cesarean section, and the other ba-
bies were delivered vaginally. In addition to the two 
premature babies, one baby, who was born to a mother 
with Alagille syndrome, died from congenital birth 
defects. The rest of the newborns survived. The mean 
birth weight was 2,797±775 g, with 38 babies (78%) 
weighing more than 2,000 g. The mean birth weight 
percentile to gestational period was 54±23. Four ba-
bies (8.5%) had a birth weight percentile of less than 
25, and 28 babies (59.6%) had a birth weight percentile 
greater than 50. Twelve patients demonstrated an in-
crease in hepatic enzymes without jaundice during 
the pregnancy. All of them responded to augmentation 
of immunosuppression. 
Conclusion. The present report reconfirms the 
safety of tacrolimus during pregnancy after LTx. Pre-
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term delivery and low birth weight seem to be a per-
sistent problem in all solid-organ transplantation un-
der any form of immunosuppression. However, 
toxemia of pregnancy and new onset of hypertension 
seem to be have a low occurrence with the use of 
tacroHmus. 
Chronic liver disease can lead to amenorrhea in women, 
and pregnancy is often not possible in women of childbearing 
age. There are reports after liver transplantation (LTx) indi-
cating that the normal menstrual cycle is restored, and that 
childbearing is possible. There are also reports of pregnancy 
during which azathioprine (Aza) and cyclosporine A (CsA)-
based (1-3) immunosuppression is administered. Tacrolimus 
was introduced in clinical trials at our center 13 years ago 
and has been used by many other centers during the last 10 
years. During the last 5 to 10 years, we have published our 
initial reports on successful pregnancies after LTx with ta-
crolimus-based immunosuppression (4, 5). 
This report updates our center's experience and examines 
the outcome of pregnancies after LTx with tacrolimus-based 
immunosuppression during the last 13 years from a single 
center. 
PATIENTS AND METHODS 
All pregnancies with tacrolimus-based immunosuppression after 
LTx were examined prospectively. The course ofthe pregnancy in the 
mother, changes in allograft function, complication in the mother, 
and immunosuppression were examined. Gestational period. type of 
delivery, birth weight, intrauterine development of the fetus, and 
congenital defect in the fetus were recorded. Intrauterine growth of 
the fetus was determined by calculating birth weight percentile 
using the scatter gram from Lubchenco, Hansman, and Boyd (6). 
RESULTS 
Overall, 37 mothers delivered 49 babies. Three mothers 
delivered three times (cases 2, 11, and 35), and six mothers 
delivered two times (cases 1, 5, 9, 10, 14, and 16). The pri-
mary diagnosis of end-stage liver failure is given in Table 1. 
Eight mothers underwent two transplants and three mothers 
underwent three transplants before pregnancy. Seven moth-
ers (18.9%) had undergone LTx at the age of 12 years or less; 
the youngest patients were 6 (case 32) and 8 years (case 31) 
at the time ofLTx. The mean age of the mother at the time of 
delivery was 29.1::6.3 years (median 27.5; range 18.3-43.4 
years). The mean interval from LTx to delivery was 
70.2::51.8 months (median 48; range 8-163 months). All 
mothers received tacrolimus for the entire gestational period. 
A total of 20 mothers received tacrolimus from the outset 
after LTx, and 17 mothers originally received esA and were 
converted to tacrolimus for ongoing rejection. They were con-
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verted to tacrolimus before pregnancy. The mean time they 
received tacrolimus before delivery was 49.9=40.8 months 
(median 31.2; range 5.8-114.8 months). 
Survival 
Mothers. Thirty-six mothers (92.3%) survived the preg-
nancy. One mother (case 32) underwent two LTxs; primipara 
at age 40 years, her infra-renal aortic graft clotted during 
labor. She developed liver failure 2 days later and died of 
fulminant gangrene of the allograft on transfer to our center 
before retransplantation could be accomplished. However, 
the newborn baby survived. Of the remaining 36 mothers, 
three died during the subsequent follow-up period. One 
mother (case 3) had a documented history of noncompliance 
with substance abuse and died as a result ofliver failure from 
chronic rejection 67 months postdelivery and 101 months 
post-LTx. Another mother (case 12) was also noncompliant 
and died of liver failure from recurrent hepatitis B virus 
infection and chronic rejection 40 months after delivery and 
84 months post-LTx. A third mother (case 7) underwent 
retransplantation 30 months postdelivery for de novo hepa-
titis C virus infection. Postoperatively, she sustained isch-
emic brain injury from respiratory failure and died 34 
months postdelivery. 
Liver Allograft. All mothers maintained liver allograft func-
tion during the pregnancy except case 32 (described previously), 
who experienced ischemic graft injury during labor. After de-
livery, one mother (case 11) lost the liver allograft from recur-
rent autoimmune hepatitis and chronic rejection. After two 
successful pregnancies, she underwent combined liver and kid-
ney transplantation 46 and 19 months after delivery after the 
first and second babies, respectively. She subsequently deliv-
ered for the third time 69 months after kidney and liver retrans-
plantation. The rest of the surviving mothers have kept their 
original graft from the time of pregnancy. 
Newborn Babies. Twenty-seven babies (55%) were deliv-
ered vaginally, and 22 babies (46.9%) were delivered by cae-
sarean section. The reasons for caesarean section are given in 
Table 1. 
Of 49 live babies, two were premature and died soon after 
delivery (cases 5 and lOa); both mothers conceived soon after 
transplantation and are described in our previous report. Of 
the remaining 47 live babies, one baby (case 35) was born to 
a mother who underwent transplantation for Alagille syn-
drome and died 4 months later from multiple congenital birth 
defects of cardiopulmonary and esophageal origin. The 
mother subsequently remarried and has two viable babies 
(cases 35b and 35c) from the second marriage. The remaining 
46 babies (25 boys and 21 girls) were alive and well at the last 
follow-up. 
Gestational Period. The mean gestational period for the 
viable babies was 36.4::'::3.2 weeks (excluding the two prema-
ture babies; range 28-40, median 37 weeks). 
Thirty-two babies (68%) had gestational periods of 36 
weeks or more. 12 babies (26%) had gestational periods rang-
ing from 32 to 36 weeks, and the remaining three babies (6%) 
had gestational periods of less than 32 weeks. 
Birth Weight 
The mean birth weight was 2,697::'::775 g (median 2,652; 
range 924-2,346 g). Thirty-eight babies (78%) weighed more 
than 2,000 g, excluding two premature babies. 
Birth Weight Percentile for Gestational Period. The mean 
birth weight percentile was 54::'::27 (range <10->90; medi-
an=50). Four babies (8.5%) had a birth weight percentile of 
less than 25, 15 babies (31.9%) had a birth weight percentile 
of 25 to 50, and the remaining 28 babies (59.6%) had a birth 
weight percentile of 50 or greater. 
Congenital Anomaly 
There was a multiple congenital defect in case 35a consist-
ing of a tracheoesophageal fistula and valvular heart disease. 
There was a nonfunctional unilateral cystic kidney in case 
14a. The baby also had an accessory nipple on the right side. 
The mother had a history of a similar abnormality in two 
sons with one extra nipple and one son with two extra nipples 
before LTx. She did not inform us initially, because she felt it 
was a familial condition. No other congenital anomaly was 
detected. 
Renal Function 
Overall, renal function before conception, during the first, 
second, and third trimesters, and after delivery remained 
stable. There was a slight improvement in mean serum cre-
atinine during the pregnancy, but this returned to baseline 
after delivery. The details of mean blood urea nitrogen and 
serum creatinine are given in Table 2. During the follow-up 
period, one patient (case 11) underwent kidney transplanta-
tion (with retransplantation of liver described earlier in the 
present report) 19 months after the second delivery. Also, one 
patient (case 30) developed end-stage renal failure 28 months 
postdelivery and is currently on hemodialysis. She had a 
longstanding history of diabetes and hypertension. One pa-
tient (case 36) passed kidney stones during the pregnancy. 
Liver Function 
Twelve pregnancies (24.5%) were associated with an in-
crease in liver enzymes without jaundice (six during preg-
nancy and six in the postpartum period). These were usually 
treated with an augmentation of baseline immunosuppres-
sion or a steroid bolus or both. None ofthe grafts were lost for 
immunologic reasons. 
Hypertension and Toxemia of Pregnancy 
Four mothers (cases 8, 10, 22, and 30) were hypertensive 
before pregnancy, which required treatment. Calcium chan-
nel blocker has been the antihypertensive agent of choice at 
our center, and usually single agent was adequate. They 
remained stable during the pregnancy, except in case lOa in 
which emergency cesarean section was required. Their ges-
tation periods were 35, 32, 38, and 38 weeks with birth 
weights of 2,594, 1,565, 2,430, and 2,585 g and birth weight 
percentiles for gestational periods of 75, 50, 25, and 25, 
respectively. 
Insulin-Dependent Diabetes Mellitus 
Three mothers (cases 4, 29, and 30) were receiving insulin 
before and during the viable pregnancy. The mean gesta-
tional periods in these three mothers were 33, 35.5, and 38 
weeks with birth weight percentiles of 40, 80, and 20, 
respectively. 
,1·: 
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TABLE 2. Liver and renal function with tacrolimus dose and concentration 
Before pregnancy First trimester Second trimester Third trimester After delivery 
Liver function (mean values) 
Bilirubin AST ALT Bilirubin AST ALT Bilirubin AST ALT Bilirubin AST ALT Bilirubin AST ALT 
0.6 35.3 38.0 0.6 31.5 32.0 0.6 37.0 3S.7 0.5 36.7 31.2 0.7 4S.7 41.6 
0.4 21.1 25.1 0.4 19.6 23.5 0.4 40.3 33.6 0.4 47.0 25.7 0.5 70.6 53.3 
0.6 27.5 32.0 0.5 26.5 28.0 0.5 27.0 24.0 0.4 27.0 23.5 0.7 2S.0 25.0 
Renal function (mean value) 
Creatinine BUN Creatinine BUN Creatinine BUN Creatinine BUN Creatinine BUN 
1.2 20.3 1.0 17.0 1.0 15.0 1.1 14.2 1.2 18.S 
0.5 7.5 0.4 6.6 0.4 6.4 0.4 S.l 0.5 10.2 
1.1 IS.5 0.9 17.0 0.9 14.0 0.9 13.0 1.1 15.0 
Mean tacrolimus--dose mg/day and whole-blood trough concentration ng/mL 
Dose Level Dose Level Dose Level Dose Level Dose Level 
9.S 7.0 9.5 7.0 9.6 4.5 9.5 4.5 10.9 5.7 
Bilirubin mgldL (1 mgldL=17 /Lmol/L, SI units), creatinine mgldL (1 mgldL=S8.4 /Lffiol/L-SI units). 
BUN, blood urea nitrogen-mgldL (1 mgldL=0.357 /Lmol/L SI units); AST, aspartate amino transferase UIL; ALT, alanine amino 
transferase UIL. 
Immunosuppression 
All patients received tacrolimus during the entire preg-
nancy period. Seventeen of the 37 mothers initially received 
CsA but were converted to tacrolimus before pregnancy. The 
mean tacrolimus dose and tacrolimus trough concentration 
before, during, and after pregnancy are given in Table 2. 
Three patients received Aza (cases 6, 11, 11c, and 36). In one 
mother (case 6), Aza was discontinued during the first tri-
mester; the other two mothers continued to take Aza during 
the pregnancy (75 and 50 mg/day), respectively. 
Prednisone 
Twelve mothers (27%) received prednisone (5-10 mg/day) 
before and at the time of conception. In two of them, the 
prednisone was discontinued during the pregnancy without 
any ill effects. 
Fludrocortisone 
Nine of the 37 mothers (25%) received fludrocortisone (0.1 
mg/day) to control hyperkalemia. 
DISCUSSION 
Tacrolimus has proven to be a potent immunosuppressive 
agent (7-11). It was first used in clinical trials 13 years ago at 
our center, and many other centers have confirmed our ini-
tial findings of safety and efficacy of the drug in clinical LTx 
(12). Its safety in pregnancy has been similarly described by 
us (5) and others U3-16). It is important to note that this is 
a case series with only 39 mothers and 49 babies, and that it 
is premature to draw a firm conclusion. 
In our previous report, we showed that the drug is trans-
mitted transplacentally and also is excreted in the breast 
milk (5); we therefore advise mothers not to breast-feed their 
babies. We also reported transient hyperkalemia and slight 
impaired renal function in the babies; this is still not a major 
problem. In :lddition. congenital anomalies are rare. One 
patient (case 9) with a unilateral renal cyst with an accessory 
nipple was probably familial. In patients with Alagille syn-
drome. congenital multiple defects are well documented. Al-
though L Tx offers the phenotypic correction ofliver function 
in Alagille syndrome, the genetic defect continues to persist 
with the risk of transmission of the defective genome to the 
offspring. One mother, who had lost her first baby as the 
result of multiple esophageal and cardiovascular pulmonary 
abnormalities, delivered two viable and healthy babies with 
a different male partner after her second marriage. Both 
babies were tested by genetic counseling and were healthy, 
indicating that the previous anomalies, in all probability, 
were not related to tacrolimus. Two premature babies con-
ceived soon after L Tx died. The general recommendation for 
women wanting to conceive post-LTx is to wait 1 to 2 years 
until overall immunosuppression is lower and graft function 
is stable. 
The cesarean section rate has remained high for a vari-
ety of reasons. As is the case with esA, preterm delivery 
remains a common occurrence without any long-term con-
sequences.(1-3, 14, 17-19). No risk factors in particular 
were identified in the present series. The rate of pre-
eclampsia, deterioration in renal function, development of 
hypertension, and rate of rejection are also reported in 
kidney transplantation with CsA (20, 21). Preterm births 
continue to be a factor reported in all of organ transplan-
tation without any long-term consequences. The median 
birth weight percentile is 50, although 10% of babies still 
have a birth weight percentile less than 25, and 32% of 
babies are born before 36 weeks of the gestational period. 
Graft loss and mothers' deaths are consistent with the rest 
of the LTx population with a 3% to 4% loss beyond 2-year 
survival (]2). One death as the result of clotting of the 
infra-renal aortic graft by external compression from the 
gravid uterus has not been reported and should be kept in 
mind by both transplant surgeons and obstetricians. For-
tunately, renal function and liver function is generally well 
preserved in this series. compared with other reports of 
~olid-organ transplantation with CsA 122-24 J. All preg-
nancies in mothers post-LTx should be considered high-
risk and followed carefully by transplant clinicians and 
obstetricians. 
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FIGURE 1. Gestation period in weeks for each pregnancy (top); birth weight for each newborn baby (middle); birth weight 
percentile based on gestation period for each newborn baby (bottom). 
CONCLUSION 
Preterm delivery, low birth weight, and the high rate of 
cesarean section with relatively lower rates of toxemia of 
pregnancy reconfirm our initial observation of the safety of 
tacrolimus use during pregnancy post-LTx. Late incidence of 
graft loss and death are comparable to that in other trans-
plant patients. Patients with infra-aortic grafts for hepatic 
arterial flow may need to be monitored with color Doppler 
ultrasonography during labor. 
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EFFECTS OF MIDDLE HEPATIC VEIN RECONSTRUCTION ON 
RIGHT LIVER GRAFT REGENERATION 
NOBUHISA AKAMATSU/ YASUHIKO SUGAWARA,l,2 JUNICHI KAN'EKO/ KEIJI SANO,l HIROSHI lMAlVfURA,l 
NORIHIRO KOKUDO,l AND MASATOSHI MAKuuCHIl 
Background. A right liver graft without the middle 
hepatic vein (MHV) trunk is now commonly used in 
living-donor liver transplantation for adult patients. 
The significance of MHV reconstruction on regenera-
tion or functional recovery of right liver grafts after 
living-donor liver transplantation, however, remains 
unclear. 
Methods. From 2000 to 2002 at the University of Tokyo 
Hospital in Tokyo, Japan, 56 adult patients received a 
right liver graft. The patients were divided into three 
groups by graft type: right liver graft without l.\1HV 
trunk or MHV reconstruction (n=17); right liver graft 
without MIN trunk, but with MIN reconstruction 
(n=27); and extended right liver graft (n=12). Regener-
ation rate and postoperative liver function were com-
pared among groups. Predictive factors associated with 
the graft regeneration were identified among clinical 
variables, including the graft type. 
Results. The regeneration rate of the right parame-
dian sector and the whole graft was lowest in the right 
liver grafts without the MHV trunk or MHV recon-
struction. The regeneration rate of the lateral sector 
was highest in this type of graft, but the difference was 
not statistically significant. The factors that signifi-
cantly correlated with the regeneration rate were pre-
operative graft volume and graft type. There was no 
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significant difference among groups in any of the liver 
function parameters. 
Conclusions. In the present series, satisfactory out-
come was independent of the type of graft used, which 
indicates that MHV reconstruction should not be omit-
ted routinely but should be performed in selected 
patients. 
Living-donor liver transplantation (LDLT) is now widely 
performed to compensate for the critical cadaveric organ 
shortage for adult patients (1). An extended right liver graft 
(2), which includes the trunk of the middle hepatic vein 
(MHV), was devised to alleviate the problem of graft size 
disparity. This type of graft, however, increases the extent of 
the donor operation and is therefore an important ethical 
issue in LDLT (3). 
A right liver graft without the MHV trunk is now com-
monly used. The graft includes the MHV and only its distal 
parts. Hepatic venous outflow of the right paramedian sector 
drains mainly into the MHV (4). The tributaries of the MHV 
consist of V8 and V5, which drains segments VIII and V, 
respectively, according to Couinaud's nomenclature for liver 
segmentation. Without caval anastomosis for drainage ofV5 
or V8, this type of graft can cause severe congestion of the right 
paramedian sector. Such congestion can lead to severe graft 
dysfunction and atrophy of the right paramedian "ector (5). 
MHV drainage into the recipient's venous system can be 
reconstructed using vein grafts (6), providing a functionmg 
liver mass comparable to an extended right liver graft (7). 
Lee and colleagues (5) emphasized the necessity of aggressive 
reconstruction of the MHV under any circumstances. In con-
trast, most of the initial cases r8-1m seemed to achieve 
successful results without MHV reconstruction. Therefore it 
remains unknown whether all right liver grafts without the 
MHV trunk require MHV drainage. 
Right liver graft for the patients was selected from the 
following three types: right liver l:,'Taft without MHV trunk or 
